LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

81.36 -0.65

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

79.78

Max

82.47

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelnas, tenkantis vienai akcijai

-0.613

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-245M

-94M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+2.83% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.1B

13B

Ankstesnė atidarymo kaina

82.01

Ankstesnė uždarymo kaina

81.36

Naujienos nuotaikos

By Acuity

34%

66%

86 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-02 17:29; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2025-12-02 16:21; UTC

Uždarbis

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2025-12-02 16:18; UTC

Uždarbis

Correction to Scotiabank Quarterly Earnings Buoyed Article

2025-12-02 23:53; UTC

Rinkos pokalbiai

Nikkei May Rise After Gains on Wall Street -- Market Talk

2025-12-02 22:48; UTC

Uždarbis

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2025-12-02 22:12; UTC

Rinkos pokalbiai

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2025-12-02 22:03; UTC

Rinkos pokalbiai

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2025-12-02 22:00; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-02 22:00; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-02 22:00; UTC

Rinkos pokalbiai

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2025-12-02 21:56; UTC

Uždarbis

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2025-12-02 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-12-02 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-02 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-02 21:44; UTC

Uždarbis

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2025-12-02 21:38; UTC

Rinkos pokalbiai

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2025-12-02 21:19; UTC

Uždarbis

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2025-12-02 20:06; UTC

Rinkos pokalbiai

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2025-12-02 19:55; UTC

Rinkos pokalbiai

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2025-12-02 19:53; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-12-02 19:53; UTC

Rinkos pokalbiai
Uždarbis

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2025-12-02 19:24; UTC

Rinkos pokalbiai

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2025-12-02 19:06; UTC

Rinkos pokalbiai

Precious Metals Step Back After Silver Sets Record -- Market Talk

2025-12-02 18:27; UTC

Įsigijimai, susijungimai, perėmimai

Kraken to Acquire Backed Finance AG

2025-12-02 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-02 17:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-02 15:17; UTC

Rinkos pokalbiai

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2025-12-02 14:47; UTC

Rinkos pokalbiai

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2025-12-02 14:38; UTC

Rinkos pokalbiai

Silver Steps Back From Record Levels -- Market Talk

2025-12-02 14:31; UTC

Rinkos pokalbiai
Uždarbis

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

2.83% į viršų

12 mėnesių prognozė

Vidutinis 84.31 USD  2.83%

Aukščiausias 110 USD

Žemiausias 65 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

15

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

86 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat